Migraine Botox consent form template

Key Takeaways

A migraine Botox consent form must document FDA-approved use (chronic migraine, 15+ headache days/month) and state it is NOT licensed for episodic migraine.

The Black Box Warning about distant spread of toxin effect is a legal requirement on every consent form.

Contraindication screening (neuromuscular disorders, pregnancy, myasthenia gravis) protects patient safety and practice liability.

Pabau’s digital forms automate consent collection, signature capture, and storage with full audit trails for regulatory compliance.

Introduction to migraine Botox consent forms

A migraine Botox consent form differs from a cosmetic Botox consent in substance, not just wording. The therapeutic indication, the FDA Black Box warning, and the injection protocol all have to appear in specific, defensible language, or the consent will not hold up under scrutiny.

Botulinum toxin has been FDA-approved for chronic migraine since 2010 and endorsed by NICE guidance (TA260) for patients with 15 or more headache days a month, yet many practices still run consent for it on a generic cosmetic form.

A well-built migraine Botox consent form protects three parties: the patient (informed, voluntary decision-making), the practice (documented understanding that reduces liability), and the clinician (evidence of informed-consent compliance for medical regulators). This guide covers what a Botox consent form for migraines must legally contain, how to customize it by jurisdiction, and how to run it inside your clinical workflow.

What is a migraine Botox consent form?

A migraine Botox consent form is a clinical document that communicates the nature, purpose, risks, benefits, and alternatives of botulinum toxin treatment for chronic migraine. Like any consent form for Botox, it records that the patient received the information, understood the treatment, and agreed to proceed voluntarily.

Unlike cosmetic Botox consent, which focuses on aesthetic outcomes, migraine consent emphasizes the therapeutic indication. That means preventing headaches through neuromuscular relaxation of scalp and neck muscles.

The form must state that Botox is FDA-approved for chronic migraine (15+ headache days/month, 8 of which are migraine days) and is NOT approved for episodic migraine (fewer than 15 days/month). This distinction is legally critical in both the US and UK.

Key sections your migraine Botox consent form must include

A compliant migraine Botox consent form follows a structured template that guides both patient and clinician through informed decision-making.

• Patient eligibility screening: Documentation of the patient’s migraine history (headache frequency, duration, prior treatments attempted).
• Treatment definition: Clear explanation of what botulinum toxin is, how it works, and the FDA/NICE approved indication (chronic migraine only).
• Injection protocol: Details of the standard 155-unit dose across 31 injection sites in the head, neck, and shoulder; clinicians administer injections every 12 weeks.
• Black Box warning: FDA-mandated disclosure of distant spread of toxin effect, dysphagia, ptosis, and other serious potential complications.
• Contraindications checklist: Screening for myasthenia gravis, pregnancy/breastfeeding, neuromuscular disorders, and active infection at injection sites.
• Risks and benefits: Realistic outcomes, expected timeline to efficacy (results typically appear 7-14 days post-injection, plateau at 30 days), and common side effects (headache, neck pain, injection site reactions).
• Alternative treatments: Brief description of other migraine prophylaxis options, such as preventive medications, lifestyle modifications, or a broader pain management treatment plan.
• Patient signature block: Signature, date, and printed name; separate clinician signature attesting to the informed consent discussion.

Why digital forms matter for migraine Botox consent

Paper consent forms introduce compliance risks:

• Missing signatures.
• Illegible handwriting.
• Forms filed in the wrong chart.
• No audit trail if a dispute arises.

Digital consent software inside practice management software like Pabau automates the process. Patients complete the form on a tablet or their phone, signatures are captured electronically, and the signed document is filed to the patient’s clinical record with a timestamped audit log.

For migraine Botox consent, this means your practice can customize the form once (adding your practice name, clinician credentials, contact details), reuse it for every patient, and ensure structured clinical records that regulators expect during audits.

Pre-treatment eligibility screening

Before presenting the migraine Botox consent form, your practice must confirm the patient meets the FDA-approved indication. The Migraine Trust confirms that UK licensing requires 15 or more headache days per month, with at least 8 of those being migraine days.

A neurological exam checklist alongside the headache history strengthens that eligibility record. Patients with fewer headache days (episodic migraine) should not receive the treatment, and the consent form must explicitly state this.

The screening section should ask:

• How many headache days per month?
• How many of those are migraine days?
• How long has this pattern persisted?
• Have you tried at least three preventive medications without adequate response?

Medi-aesthetic patient consultation best practices recommend documenting these details before treatment, not after.

Contraindication checklist and patient safety

Your migraine Botox consent form must include an explicit contraindication checklist. This protects the patient by preventing unsafe treatment and protects the practice by demonstrating due diligence. Key contraindications include:

• Myasthenia gravis or other neuromuscular junction disorders.
• Pregnancy or breastfeeding (botulinum toxin is contraindicated).
• Known hypersensitivity to botulinum toxin or any ingredient.
• Infection or skin conditions at proposed injection sites.
• Recent use of antibiotics that potentiate neuromuscular blockade.

The form should require the patient to initial each “no” response, confirming they do not have the listed condition. This creates a documented safety record.

Black Box warning disclosure

The FDA mandates a Black Box Warning on all botulinum toxin products describing the risk of distant spread of toxin effect. This means the medication’s paralytic action can extend beyond the injection site and cause serious complications like dysphagia (difficulty swallowing), weakness, or breathing difficulty.

Your migraine Botox consent form must include this warning verbatim or substantially equivalent language. It cannot be buried in small print or omitted.

Example language: “DISTANT SPREAD OF TOXIN EFFECT: The effects of botulinum toxin may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have included asthenia, diplopia (double vision), dysphonia (voice hoarseness), dysphagia, and dysarthria (difficulty speaking or articulating), and shortness of breath, and death. Patients have reported these symptoms up to several weeks after injection.”

Injection protocol: migraine Botox injection sites and units

Patients deserve to know exactly how the treatment will be administered. The Botox protocol for migraine follows the PREEMPT paradigm: a fixed 155 units delivered across 31 injection sites, with an optional “follow-the-pain” escalation up to 195 units across 39 sites.

The fixed sites span:

• The frontalis, procerus, and corrugator muscles of the forehead.
• The temporal regions.
• The occipital areas.
• The cervical paraspinal muscles.
• The trapezius.

Each site receives approximately 5 units (0.1 mL), and injections are repeated every 12 weeks.

Your consent form should describe these sites in plain language, ideally with a simple diagram or reference to anatomical regions, so patients can visualize the treatment area. This transparency builds trust and reduces post-treatment complaints.

Who can administer treatment and regulatory compliance

In the US, licensed medical professionals (MDs, DOs, NPs, and PAs under supervision) may administer Botox for migraine. In the UK, nurse practitioner botox qualifications allow certain nurses and nurse practitioners to administer injections, but only under the direction of a consultant neurologist or headache specialist, and only for chronic migraine, not cosmetic use.

Your consent form should identify your practice’s administering clinician and their credentials, confirming they meet your jurisdiction’s regulatory requirements.

Documentation requirements and regulatory compliance

Once the patient has signed the migraine Botox consent form, clinical documentation best practices call for storing it in the patient’s clinical record with a note on who obtained consent and when. Retention periods for the record itself are set by state law, commonly 5-10 years and often longer for minors, rather than by HIPAA directly.

HIPAA separately requires practices to retain their own compliance documentation for a minimum of 6 years. In the UK, CQC inspectors will request consent documentation during visits, and digital, timestamped records demonstrate compliance.

Record what you discussed:

• Does the patient understand the indication (chronic migraine, 15+ days/month)?
• Do they know the standard protocol (155 units, 31 sites, every 12 weeks)?
• Are they aware of the Black Box warning?
• Did they ask questions, and how were they answered?

This narrative summary, stored alongside the signed consent, is your legal protection.

Customization by jurisdiction

For US-based practices: Your consent form should reference FDA approval (2010) and the Black Box Warning. State laws vary on informed consent specifics, so review your state’s medical board guidance. HIPAA compliance requires secure storage of the signed consent.

For UK-based practices: Reference GMC decision making and consent guidance and NICE TA260. Note that Botox for migraine is only available via a headache specialist or consultant neurologist; your form should confirm this. CQC registration is mandatory, and CQC inspectors audit consent documentation regularly.

Implementation for skin clinics and aesthetic practices

Many aesthetic and skin practices now offer Botox for migraine alongside cosmetic offerings. The challenge is preventing form confusion, since a cosmetic Botox consent differs significantly from a migraine consent.

Skin clinic practice management systems let you create separate form templates, “Botox for Cosmetic Use” and “Botox for Chronic Migraine.” Your admin can assign the correct form based on the service booked, reducing errors and keeping the practice compliant.

Consent and consultation flow

Best practice is a structured workflow:

1. Initial consultation: discuss migraine history and eligibility.
2. Present the consent form and review each section aloud.
3. Allow time for questions.
4. Patient signs the form.
5. Clinician countersigns.
6. File the signed copy to the patient record before administering treatment.

Patient consultation documentation templates embed this workflow, sending automated reminders to complete consent before the injection appointment.

Automate your migraine botox consent process

Collect, sign, and file consent forms digitally with timestamped audit trails that regulators expect.

Book a demo

Risks, benefits, and setting realistic expectations

Your migraine Botox consent form should include realistic timelines and outcome ranges, and it should name the common side effects of Botox for migraine headaches so expectations are set in writing. Benefits typically appear 7-14 days post-injection and plateau at 30 days.

Results vary: some patients report a 50%+ reduction in headache days, while others see a more modest improvement. A quality of life assessment at follow-up gives both patient and practice a consistent way to track that change.

Common side effects include mild headache, neck pain, and injection site bruising, usually resolving in 5-7 days. Serious complications such as dysphagia or weakness are rare when the clinician uses proper injection technique.

State that Botox for migraine is not a cure. It is a preventive therapy requiring ongoing treatment every 12 weeks. Patients may discontinue treatment at any time, and effects wear off within 12 weeks of the last injection.

Conclusion

A well-built migraine Botox consent form is the foundation of ethical, compliant chronic migraine treatment. It demonstrates respect for patient autonomy, protects your practice from liability, and meets regulatory expectations in both the US and UK.

The template above provides the key sections. Customize it for your jurisdiction, practice name, and clinician credentials, then build it into your workflow. When practices shift from paper to medical spa software with digital form capture, consent collection gets easier and records stay audit-ready.

Continue your research

Need a structured patient consultation template? Performing consultations that convert provides a step-by-step framework for discussing treatment options and building patient confidence before administering injections.

Want to automate your intake process? Capture forms software enables practices to collect patient history, consent, and eligibility screening digitally on a single device.

Interested in compliance best practices? Medical spa compliance checklist outlines documentation, storage, and regulatory requirements for aesthetic practices operating in the US and UK.

Frequently asked questions